Visterra

Visterra

Biotechnology, 275 2nd Ave Fl 4, Waltham, Massachusetts, 02451, United States, 51-200 Employees

visterrainc.com

  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is VISTERRA

Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat d...

Read More

map
  • 275 2nd Ave Fl 4, Waltham, Massachusetts, 02451, United States Headquarters: 275 2nd Ave Fl 4, Waltham, Massachusetts, 02451, United States
  • 2008 Date Founded: 2008
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 621511 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from VISTERRA

Visterra Org Chart and Mapping

Employees

Nicole Akramoff

Associate Director Clinical Operations

John Grossman

Senior Director, Head of Human Resources

Stephen Torra

Senior Director Enterprise Services

Chris Kiefer

Chief Administrative Officer (Cao)

Courtney Murphy

Scientist, Purification Process Development

Zach Shriver

Chief Scientific Officer

Jesus Mena

Nonclinical Study Manager

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Visterra

Answer: Visterra's headquarters are located at 275 2nd Ave Fl 4, Waltham, Massachusetts, 02451, United States

Answer: Visterra's phone number is 61********

Answer: Visterra's official website is https://visterrainc.com

Answer: Visterra's revenue is $10 Million to $25 Million

Answer: Visterra's SIC: 2834

Answer: Visterra's NAICS: 621511

Answer: Visterra has 51-200 employees

Answer: Visterra is in Biotechnology

Answer: Visterra contact info: Phone number: 61******** Website: https://visterrainc.com

Answer: Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Our proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, we are developing a robust pipeline of novel therapies for patients with unmet needs. Our most advanced program is in Phase 2 clinical development. In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access